Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized controlled clinical trial to compare the short and long outcomes of Neoadjuvant chemotherapy with postoperative chemotherapy in patients with resectable locally advanced colon cancer
For resectable locally advanced colon cancer, the preferred treatment is colectomy with en bloc removal of the regional lymph nodes followed by chemotherapy of about 6 months. However, surgery may postpone the administration of chemotherapy due to postoperative complications such as anastomosis leakage, abdominal infection, thus leads to a poor survival. Some scholars suggested that for patients with locally advanced colon cancer, chemotherapy given before surgery might shrink or downstage tumor, facilitate surgery and promote a better oncological outcome. Whether adjuvant chemotherapy benefits these patients with better outcome still remains controversial.
In this study, eligible patients will be randomly allocated to receive either adjuvant chemotherapy or not. For patients receiving adjuvant chemotherapy, surgery will be performed 3-4 weeks later. Preoperative and postoperative chemotherapy will be given for a total of about 6 months. For patients receiving no preoperative chemotherapy, chemotherapy will be given for about 6 months postoperatively. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy. Patients will be followed up every 3 months for 2 year, every 6 months for 3 years postoperatively.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Postoperative chemotherapy | Active Comparator | Patients receive 6 months of chemotherapy after surgery. |
|
| Neoadjuvant chemotherapy | Experimental | Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Postoperative chemotherapy | Drug | Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy. |
| Measure | Description | Time Frame |
|---|---|---|
| disease-free survival | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| overall survival | 3 years | |
| recurrence-free survival | 3 years | |
| local recurrence rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnant patient;
History of psychiatric disease;
Use of systemic steroids;
Simultaneous multiple primary colorectal cancer;
Preoperative imaging examination results show:
Postoperative pathology of T1-T2 N0;
History of any other malignant tumor in recent 5 years;
Patients need emergency operation: mechanic ileus, perforation.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yueming Sun, PhD | Contact | 02568136026 | jssym@vip.sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Fumin Zhang, Professor | Ethics Committee of the First Affiliated Hospital, Nanjing Medical University, Jiangsu Province Hospital | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003110 | Colonic Neoplasms |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004338 | Drug Combinations |
| C410216 | Folfox protocol |
| D020360 | Neoadjuvant Therapy |
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Neoadjuvant chemotherapy | Drug | Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy. |
|
|
| 3 years |
| length of postoperative hospital stay | Length of postoperative hospital stay is defined as a duration between surgery and first discharge. An expected average is 10 days. | 30 days |
| early complication rate | Early complication is defined as a complication that occurred between the finish of the surgery and postoperative day 30. Complications includes anastomotic leakage, anastomotic bleeding, chyle leakage, wound infection, pulmonary embolism, myocardial infarction et al.The Clavien-Dindo Classification of Surgical Complications will be applied to access the degree of severity of postoperative complications. | 30 days |
| operative time | 1 day |
| number of lymph nodes retrieved | 1 day |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |